IFF Pharma Solutions announced its participation in CPHI 2024 in Milan, Italy, from October 8-10, where it will highlight new product launches and technologies for the pharmaceutical and biotech industries. The company is celebrating over 75 years as an excipient manufacturer, showcasing its legacy in the field.
The focus at CPHI 2024 will be on solutions for nitrosamine mitigation, including a new portfolio of low nitrite excipients. Additionally, IFF Pharma Solutions will present ultrapure alginate biopolymers, which are designed for next-generation therapeutic development.
These innovations underscore IFF's commitment to addressing critical industry concerns like nitrosamine risk and advancing pharmaceutical formulations. The introduction of specialized excipients aims to enhance product safety and performance for its customers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.